the acorda therapeutics ( acorda ) launch has been a gradual than expected. however, multiple inputs continue to support our conviction that a substantial product and indeed a standard of care in the treatment of OFF periods in Parkinson's. these inputs include our own formal market research and independent market research. we will discuss key events in the second quarter and discuss key issues that are discussed in this article. we will discuss some key and insights, and we will discuss the financials.